We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$498M
AUM Growth
+$258M
Cap. Flow
+$49.1M
Cap. Flow %
9.86%
Top 10 Hldgs %
69.52%
Holding
145
New
57
Increased
20
Reduced
22
Closed
41

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$6.99M
3
MRNA icon
Moderna
MRNA
+$3.94M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$3.78M
5
MTVA
MetaVia Inc
MTVA
+$3.18M

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$2.89M
2
ENLV icon
Enlivex Ltd
ENLV
+$2.31M
3
NOVN
Novan, Inc. Common Stock
NOVN
+$2.11M
4
OTLK icon
Outlook Therapeutics
OTLK
+$1.94M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.32%
2 Industrials 0.26%
3 Technology 0.12%
4 Consumer Discretionary 0.09%
5 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
PUT
Biogen
BIIB
$30.4B
$68.1M 13.66%
+2,544
New +$765K
BIIB icon
2
CALL
Biogen
BIIB
$30.4B
$48.3M 9.69%
+1,804
New +$542K
XLV icon
3
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
$46.4M 9.31%
4,634
-1,219
-21% -$120K
OEF icon
4
PUT
iShares S&P 100 ETF
OEF
$19.8B
$41.6M 8.35%
2,954
+254
+9% +$34.2K
BCLI
5
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$33.2M 6.66%
622
+353
+131% +$38.1K
BIIB icon
6
Biogen
BIIB
$30.4B
$27.8M 5.58%
+103,902
New +$31.2M
XNTK icon
7
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$25.9M 5.2%
2,313
+544
+31% +$47.8K
SPY icon
8
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$18.8M 3.78%
610
-890
-59% -$261K
MRNA icon
9
PUT
Moderna
MRNA
$22.1B
$18.7M 3.76%
+2,915
New +$160K
OEF icon
10
CALL
iShares S&P 100 ETF
OEF
$19.8B
$17.6M 3.54%
1,239
+665
+116% +$89.5K
SPY icon
11
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$17.3M 3.47%
561
+227
+68% +$66.4K
XLV icon
12
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
$10.5M 2.11%
105,280
+70,870
+206% +$6.99M
GLD icon
13
CALL
SPDR Gold Trust
GLD
$131B
$7.3M 1.46%
436
-538
-55% -$86.8K
INO icon
14
CALL
Inovio Pharmaceuticals
INO
$84.7M
$6.72M 1.35%
+208
New +$33.4K
XLV icon
15
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
$6.67M 1.34%
666
-334
-33% -$33K
SRNE
16
PUT
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$6.33M 1.27%
10,081
+8,512
+543% +$32.6K
INO icon
17
PUT
Inovio Pharmaceuticals
INO
$84.7M
$5.82M 1.17%
+180
New +$28.9K
KYNB
18
PUT
Kyntra Bio
KYNB
$28.2M
$5.7M 1.14%
56
+42
+300% +$39K
PLUR icon
19
PUT
Pluri
PLUR
$18.1M
$5.42M 1.09%
767
+505
+193% +$33K
MRNA icon
20
Moderna
MRNA
$22.1B
$4.62M 0.93%
+71,893
New +$3.94M
CVM.WS
21
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
$4.6M 0.92%
3,084
+832
+37% +$1.24M
AVEO
22
PUT
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$3.76M 0.76%
7,307
-2,941
-29% -$18.6K
GLD icon
23
PUT
SPDR Gold Trust
GLD
$131B
$3.6M 0.72%
215
-1,181
-85% -$190K
AZN icon
24
PUT
AstraZeneca
AZN
$267B
$3.57M 0.72%
+338
New +$34.9K
SRNE
25
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$3.24M 0.65%
+5,155
New +$19.7K
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sabby Management held 145 positions worth $498M, up 107% from $241M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management deployed $49.1M of net new capital in Q2 2020, opening 57 new positions and adding to 20 existing holdings. Its largest new stake was Biogen: 103,902 shares worth $27.8M.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 7.3% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Enlivex Ltd, an estimated $2.31M trimmed.

  • Sabby Management's largest Q2 2020 buy was Biogen: 103,902 shares worth $27.8M.
  • Sabby Management added most to State Street Health Care Select Sector SPDR ETF in Q2 2020, an estimated $6.99M increase.
  • Sabby Management's biggest Q2 2020 reduction was Enlivex Ltd, cutting an estimated $2.31M.
  • Sabby Management fully exited SPDR Gold Trust in Q2 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 70% of its $498M portfolio in Q2 2020.
  • Sabby Management opened 57 new positions and closed 41 in Q2 2020.
  • Sabby Management's portfolio value rose 107% quarter-over-quarter to $498M.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.